4′-EPI-Adriamycin in Metastatic Renal Cancer
4′-epi-Adriamycin (4′-epi-ADR) is a stereoisomer of Adriamycin Preliminary observations have indicated cytostatic activity of 4′-epi-ADR in metastatic renal cancer (1). A phase II study was therefore performed in order to define the efficacy of 4′-epi-ADR in this malignancy.
KeywordsRenal Cancer Renal Cell Cancer Cytostatic Drug Systolic Time Interval Cytostatic Activity
Unable to display preview. Download preview PDF.
- 1.V. Bonafante, G. Bonadonna, F. Villani, G. Di Fronzo, A. Martini, and A.M. Casazza, Preliminary Phase I Study of 4′-Epi-Adriamycin, Cancer Treat. Rep. 63: 915 (1979).Google Scholar